Trial of Tocilizumab in Giant-Cell Arteritis | Zendy

John H. Stone | Zendy; Katie Tuckwell | Zendy; Sophie Dimonaco | Zendy; Micki Klearman | Zendy; Martin Aringer | Zendy; Daniël Blockmans | Zendy; Elisabeth Brouwer | Zendy; María C. Cid | Zendy; Bhaskar Dasgupta | Zendy; Jürgen Rech | Zendy; Carlo Salvarani | Zendy; Georg Schett | Zendy; Hendrik SchulzeKoops | Zendy; Robert Spiera | Zendy; Sebastian Unizony | Zendy; Neil Collinson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trial of Tocilizumab in Giant-Cell Arteritis

Author(s) -

John H. Stone,

Katie Tuckwell,

Sophie Dimonaco,

Micki Klearman,

Martin Aringer,

Daniël Blockmans,

Elisabeth Brouwer,

María C. Cid,

Bhaskar Dasgupta,

Jürgen Rech,

Carlo Salvarani,

Georg Schett,

Hendrik SchulzeKoops,

Robert Spiera,

Sebastian Unizony,

Neil Collinson

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1613849

Subject(s) - tocilizumab , giant cell arteritis , medicine , tapering , glucocorticoid , giant cell , prednisolone , arteritis , interleukin 6 , vasculitis , pathology , rheumatoid arthritis , cytokine , computer graphics (images) , computer science , disease

Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of glucocorticoids is associated with side effects. The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoid tapering was studied in patients with giant-cell arteritis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research